Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Scopolamine Transdermal System 1 mg/3 days. (USRLD: Transderm Scop Transdermal System 1 mg/3 days). This is the fifth ANDA approval
![Zydus Lifesciences receives USFDA approval for Scopolamine Transdermal System](https://img.easybranches.com/uploads/news/2024/08/zydus-lifesciences-receives-usfda-approval-for-scopolamine-transdermal-system.jpg)
Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!
Easy Branches
34/17 Moo 3 Chao fah west Road, Phuket, Thailand, PhuketCall: 076 367 766
info@easybranches.comZydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Scopolamine Transdermal System 1 mg/3 days. (USRLD: Transderm Scop Transdermal System 1 mg/3 days). This is the fifth ANDA approval